<DOC>
	<DOC>NCT02024932</DOC>
	<brief_summary>The purpose of this study is to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Muscular Disorders, Atrophic</mesh_term>
	<mesh_term>Bulbo-Spinal Atrophy, X-Linked</mesh_term>
	<criteria>Genetic diagnosis of SBMA with symptomatic muscle weakness Able to complete 2 minute timed walk Serum IGF1 level less than or equal to 170 ng/mL Medically treated diabetes mellitus or known history of hypoglycemia History of Bell's palsy Treatment with systemic steroids &gt; 10 mg/day (or equivalent dose); androgens or androgen reducing agents; systemic beta agonists; or other muscle anabolic drugs within the previous 3 months History of cancer, other than nonmelanomatous skin cancer Retinopathy Papilledema Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>